Sign In
Buy TRUMY
Terumo Earnings Calls
| Release date | May 15, 2026 |
| EPS estimate | $0.110 |
| EPS actual | $0.110 |
| Revenue estimate | 1.844B |
| Revenue actual | 1.891B |
| Revenue Surprise | 2.53% |
| Release date | Feb 13, 2026 |
| EPS estimate | $0.145 |
| EPS actual | $0.140 |
| EPS Surprise | -3.65% |
| Revenue estimate | 1.859B |
| Revenue actual | 1.933B |
| Revenue Surprise | 3.97% |
| Release date | Nov 12, 2025 |
| EPS estimate | $0.161 |
| EPS actual | $0.160 |
| EPS Surprise | -0.683% |
| Revenue estimate | 1.753B |
| Revenue actual | 1.865B |
| Revenue Surprise | 6.38% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.166 |
| EPS actual | $0.200 |
| EPS Surprise | 20.77% |
| Revenue estimate | 1.797B |
| Revenue actual | 1.795B |
| Revenue Surprise | -0.0781% |
Last 4 Quarters for Terumo
Below you can see how TRUMY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $18.67 |
| EPS estimate | $0.166 |
| EPS actual | $0.200 |
| EPS surprise | 20.77% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $17.00 |
| Aug 04, 2025 | $17.31 |
| Aug 05, 2025 | $17.21 |
| Aug 06, 2025 | $17.32 |
| Aug 07, 2025 | $18.67 |
| Aug 08, 2025 | $18.60 |
| Aug 11, 2025 | $18.55 |
| Aug 12, 2025 | $18.63 |
| Aug 13, 2025 | $18.86 |
| 4 days before | 9.82% |
| 4 days after | 1.02% |
| On release day | -0.375% |
| Change in period | 10.94% |
| Release date | Nov 12, 2025 |
| Price on release | $15.25 |
| EPS estimate | $0.161 |
| EPS actual | $0.160 |
| EPS surprise | -0.683% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $16.05 |
| Nov 07, 2025 | $16.24 |
| Nov 10, 2025 | $16.42 |
| Nov 11, 2025 | $16.38 |
| Nov 12, 2025 | $15.25 |
| Nov 13, 2025 | $15.17 |
| Nov 14, 2025 | $15.33 |
| Nov 17, 2025 | $15.28 |
| Nov 18, 2025 | $14.96 |
| 4 days before | -4.98% |
| 4 days after | -1.90% |
| On release day | -0.525% |
| Change in period | -6.79% |
| Release date | Feb 13, 2026 |
| Price on release | $14.65 |
| EPS estimate | $0.145 |
| EPS actual | $0.140 |
| EPS surprise | -3.65% |
| Date | Price |
|---|---|
| Feb 09, 2026 | $13.34 |
| Feb 10, 2026 | $13.61 |
| Feb 11, 2026 | $13.59 |
| Feb 12, 2026 | $13.41 |
| Feb 13, 2026 | $14.65 |
| Feb 17, 2026 | $12.53 |
| Feb 18, 2026 | $12.61 |
| Feb 19, 2026 | $12.76 |
| Feb 20, 2026 | $12.65 |
| 4 days before | 9.82% |
| 4 days after | -13.67% |
| On release day | -14.47% |
| Change in period | -5.19% |
| Release date | May 15, 2026 |
| Price on release | $12.68 |
| EPS estimate | $0.110 |
| EPS actual | $0.110 |
| Date | Price |
|---|---|
| May 11, 2026 | $12.39 |
| May 12, 2026 | $12.16 |
| May 13, 2026 | $12.28 |
| May 14, 2026 | $12.18 |
| May 15, 2026 | $12.68 |
| May 18, 2026 | $14.38 |
| May 19, 2026 | $14.35 |
| May 20, 2026 | $14.84 |
| May 21, 2026 | $14.70 |
| 4 days before | 2.32% |
| 4 days after | 15.93% |
| On release day | 13.41% |
| Change in period | 18.62% |
Terumo Earnings Call Transcript Summary of Q1 2026
Terumo delivered a strong FY'25 Q1: record quarterly revenue of JPY 260 billion and record adjusted operating profit of JPY 55.9 billion. Revenue grew ~6% excluding FX, driven by strength in the U.S. and China, with Cardiovascular (TIS, Neuro) and TBCT (plasma innovation/Rika deployment, cell collection) as key contributors. Gross margin outperformance was driven by pricing measures, productivity (VC score), and favorable FX on inventory; price actions contributed materially (management cited roughly JPY 4.0 billion from pricing in Q1). Free cash flow was JPY 10.5 billion, down versus prior year due to higher inventories and tariff-related impacts. Management revised the estimated full-year tariff hit down to about JPY 10 billion (from JPY 17.5 billion) and expects most tariff effects to materialize in H2; they plan to mitigate tariffs by passing through price increases where feasible. Some businesses (TMCS, certain pharma CDMO deliveries) saw temporary declines due to divestitures, supply or timing delays, but company-wide guidance for the fiscal year was maintained given the Q1 upside and expected continued pricing/volume strength. Management highlighted continued cost control, ongoing profitability-improvement initiatives, and completion/optimization progress in Rika/plasma facilities.
